Melbourne, Australia
Melbourne, Australia

Time filter

Source Type

IRVINE, Kalifornien (USA)--(BUSINESS WIRE)--Axonics Modulation Technologies Inc., Entwickler des ersten wiederaufladbaren Sakral-Neuromodulationssystems (r-SNM™) für die Behandlung von Harn- und Stuhlinkontinenz, hat heute angekündigt, dass erste Ergebnisse seiner prospektiven klinischen Multizentrumsstudie erstmals auf dem Weltkongress der International Neuromodulation Society (INS) am 30. Mai 2017 in Edinburgh, Schottland, präsentiert werden sollen. „Das Axonics-r-SNM System wurde von den Patienten, von den beteiligten Forschern und vom klinischen Personal äußerst gut angenommen“, sagte Raymond W. Cohen, Chief Executive Officer von Axonics. „Die Studie, mit der die Sicherheit und Wirksamkeit des Produkts bestätigt werden sollte, übertraf ihre Zielsetzung sogar. Der Schwerpunkt unserer Arbeit liegt jetzt mehr darauf, eine Pivotalstudie in den USA durchzuführen und die Zulassung der FDA zu erhalten. In der Zwischenzeit freuen wir uns jedoch darauf, unser Produkt für Patienten in ausgewählten internationalen Zentren verfügbar zu machen.“ Das Axonics r-SNM System hat im Juni 2016 die europäische CE-Kennzeichnung und im Dezember 2016 die Zulassung von Health Canada für die Behandlung von Blasenhyperaktivität, Harnretention und Stuhlinkontinenz erhalten. Von diesen Erkrankungen sind in den USA und Europa über 100 Millionen Erwachsene betroffen. SNM ist eine erstattungsfähige und von der FDA zugelassene Therapie, die sich als wirksame, dauerhafte Behandlung bewährt und in Europa und in den USA in den letzten zwei Jahrzehnten mehr als 250.0000 Patienten geholfen hat. Axonics hat vor, in der zweiten Jahreshälfte 2017 eine US-FDA klinische Pivotalstudie für hyperaktive Blasenpatienten in ausgewählten Zentren in den USA, Kanada und Europa zu starten. Über Axonics Modulation Technologies Inc. Axonics mit Firmensitz in Irvine, Kalifornien ist ein wagniskapitalfinanziertes Unternehmen in Privatbesitz, das eine neuartige, implantierbare Neuromodulationstechnologie für Patienten mit Harn- und Stuhlinkontinenz entwickelt hat, die auch für mehrere weitere klinische Indikationen genutzt werden kann. Das Axonics r-SNM System besteht aus einem aufladbaren Mini-Stimulator, der mindestens 15 Jahre funktionieren wird, einem für reduzierte Ladezeit und minimale Erhitzung optimierten Ladesystem, einer patientenfreundlichen Fernsteuerung und einem intuitiven Programmierer für den Kliniker, die die Elektrodenplatzierung und Programmierung der Leitung erleichtert. Die Investoren sind Edmond de Rothschild Investment Partners, Advent Life Sciences, NeoMed Management, Legend Capital, Cormorant Asset Management und The Alfred E. Mann Foundation. Weitere Informationen finden Sie auf der Unternehmens-Website unter www.axonicsmodulation.com.


IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, announced today that the United States Patent and Trademark Office has granted Axonics four new U.S. patents relating to its implantable sacral neuromodulation technology. “The diverse and rapid expansion of the Axonics U.S. patent portfolio further demonstrates the level of innovation applied by our Company in addressing the unmet needs of clinicians and patients relating to implantable Sacral Neuromodulation. With these four new U.S. patents, we now have 73 granted and 78 pending patent applications in our portfolio in various jurisdictions around the world,” said Raymond W. Cohen, Axonics Chief Executive Officer. The Axonics patent portfolio represents technology internally developed by Axonics and under license from the Alfred Mann Foundation. The Axonics r-SNM System® received European CE Mark approval in June 2016 and Health Canada approval in December 2016 for the treatment of overactive bladder (including urinary urge incontinence and urinary urgency-frequency), urinary retention, and fecal incontinence. The Company has completed enrollment of its RELAX-OAB multi-center post-market clinical study for patients with overactive bladder in select centers in the Netherlands, Belgium, France and the UK. Axonics anticipates initiating a U.S. FDA pivotal clinical study for overactive bladder patients in select centers in the U.S., Canada and Europe in the second half of 2017. The Axonics neuromodulation platform includes, among other innovations, a miniaturized rechargeable implantable neuromodulation stimulator that is approximately one-fourth the size of the smallest currently marketed rechargeable neuromodulation devices and can be directed toward numerous clinical applications. The Axonics stimulator is qualified to last at least 15 years in the body and needs to be recharged once every week or two for approximately one hour via a charging system designed to optimize ease of use and patient comfort. In addition, the Axonics platform features a key-fob sized, patient-friendly remote control and an intuitive clinician programmer that will guide and support physician implanters throughout the clinical procedure, from lead placement to programming. Axonics’ initial clinical application for its technology is Sacral Neuromodulation (SNM) for the treatment of urinary and fecal dysfunction which affects over 100 million adults in the U.S. and Europe. SNM is a reimbursed FDA-approved therapy that has proven to be an effective and durable treatment widely used in Europe and the U.S. for the past two decades with more than 200,000 patients having benefited from the therapy to date. Axonics, based in Irvine, CA, is a privately-held company developing novel implantable neuromodulation technology directed toward a number of clinical indications. Investors include Edmond de Rothschild Investment Partners, Advent Life Sciences, NeoMed Management, Legend Capital, Cormorant Asset Management and The Alfred E. Mann Foundation. For more information, visit the Company’s website at www.axonicsmodulation.com.


News Article | February 28, 2017
Site: www.marketwired.com

BELLEVUE, WA--(Marketwired - February 28, 2017) - Today, corporate wellness technology company Limeade announced two speakers headlining Limeade Engage -- a conference for HR leaders to transform employee engagement and rethink the way we work. Keynote speakers include Diana Nyad, record-breaking athlete, inspirational speaker and author of "Find A Way" and Dr. Barry Schwartz, popular TED speaker and author of "Why We Work." The event will take place in Seattle on May 2-3rd, 2017. "Work doesn't have to be draining. In fact, it can bring meaning and joy into our lives. As HR leaders we should feel empowered to drive this transformation at our organizations," said Steven Parker, vice president of customer success at Limeade and former HR executive. "Diana's incredible story and Barry's research will help Limeade Engage attendees discover that purpose is a critical dimension of well-being, and that a fulfilled workforce drives better business results." Accomplished Speakers Diana Nyad is a record-breaking athlete, author and inspirational speaker. At the age of sixty-four, she became the first person to swim from Cuba to Florida without the aid of a shark cage, swimming 111 miles in fifty-three hours from Havana to Key West. Her world records, circling Manhattan Island and crossing the 102.5 miles between the Bahamas and Florida, led to inductions into many Halls of Fame, including the International Women's Sports Hall of Fame. Nyad is a uniquely passionate speaker who wrote three books and became a prominent sports broadcaster, filing compelling reports for NPR, ABC's Wide World of Sports, Fox Sports, and The New York Times. Dr. Barry Schwartz is the author of more than 10 books including, "The Paradox of Choice" (2005) and "Why We Work" (2015), an eye-opening, groundbreaking tour of the purpose of work in our lives. With grant support from the National Science Foundation, The Alfred P. Sloan Foundation, and the MacArthur Foundation, Schwartz published more than 100 journal articles. Schwartz is a professor of psychology at Swarthmore College, and a fellow of both the American Psychological Association and the Association for Psychological Science. "Dr. Schwartz will reveal how to find meaning in ordinary work, and Diana will inspire us to find it in the extraordinary," said Parker. "HR leaders will leave Limeade Engage inspired and prepared to apply these insights to their work." For more information on Limeade Engage, event details and registration, please visit www.limeade.com/engage or join the conversation on Twitter using #LimeadeEngage. About Limeade Limeade is a corporate wellness technology company that drives real employee engagement. Limeade takes a whole-person approach to well-being, amplifies an organization's commitment to its employees and delivers smart technology that fits how people work today. Employees earn points and rewards for taking steps to improve, while employers experience better business results. Recognized for its own award-winning culture, Limeade helps the world's best companies develop happier, healthier and more productive employees. Learn more at www.limeade.com.


News Article | August 22, 2016
Site: news.mit.edu

MIT Department of Nuclear Science and Engineering (NSE) professors Jacopo Buongiorno and Dennis Whyte were awarded a grant from the Alfred P. Sloan Foundation of $1 million to launch a new Future of Nuclear Energy Technologies study. Buongiorno and Whyte will work with seven MIT faculty members from across the Institute, as well as two Harvard University faculty and two external consultants in a multidisciplinary effort. The goal of the study will be to conduct an objective assessment of the opportunities and challenges affecting the ability of nuclear energy technologies in meeting U.S. and global energy needs in a carbon-constrained world. This study is particularly timely as the landscape and boundary conditions for nuclear energy have drastically changed in the past six-to-eight years due to a number of contributing factors. The study will be conducted over two years and will assess the prospects for innovative nuclear technologies, business models, and governance mechanisms to accelerate the transition to a lower-carbon energy system. It also comes as the MIT Energy Initiative (MITEI) is launching eight Low-Carbon Energy Centers to advance specific technology areas crucial to addressing climate change, two of which are focused on nuclear energy: the MIT Center for Advanced Nuclear Energy Systems, led by Buongiorno; and the Center for Fusion Research, led by Whyte. The centers bring together faculty from across the Institute and employ an innovative model that allows multiple sponsors to collaborate on high-risk, high-reward research programs while also developing their own individual research portfolios. Multidisciplinary research projects will be key components of the new centers. This study is the next project in MITEI’s “Future of…” research series, in-depth overviews of specific energy sources containing detailed recommendations meant to shape and influence policy debates and development, technology choices, and future research. Past “Future of…” studies — the most recent of which was The Future of Solar Energy — have proved useful to members of Congress and the executive branch of government; industry leaders; and the informed public. The multidisciplinary team includes: Jacopo Buongiorno of NSE, Michael Corradini of the University of Wisconsin at Madison and MIT, Dennis Whyte of NSE, and David Petti of Idaho National Laboratory and MIT, all experts in nuclear technology, safety, and regulations; Jessika Trancik of MIT's Institute for Data, Systems, and Society, Jessica Lovering of the Breakthrough Institute, and Robert Varrin of Dominion Engineering, all experts in cost estimates of nuclear power plant systems and other energy systems; Richard Lester of NSE and Joe Lassiter of Harvard Business School, experts in innovation finance, policy, and management; John Parsons of the MIT Sloan School of Management, an expert in energy/electricity markets; Charles Forsberg of NSE and Bilge Yildiz of NSE, experts in energy storage, synthetic fuels, and nuclear hydrogen; and Steven Ansolabehere of Harvard's Department of Government, an expert in public opinion. The Alfred P. Sloan Foundation gives endowment-funded grants primarily to support original research and broad-based education related to science, technology, economic performance and the quality of American life. The foundation is unique based in its focus on science, technology, and economic institutions.


IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal dysfunction, announced today that the first Fecal Incontinence patients were successfully implanted at the University Hospital Southampton NHS Foundation Trust in Southampton, United Kingdom. Two patients were implanted by Thomas Dudding M.D., FRCS, Consultant, Colorectal & Pelvic Floor Surgeon. Dr. Dudding is internationally recognized as an expert in the use of neurostimulation for bowel control and the treatment of Fecal Incontinence and has extensive research publications in the field. The implants are part of a 12 patient evaluation designed to confirm the performance of the Axonics rechargeable SNM System as an aid in the treatment of the symptoms of Fecal Incontinence. “In just a few weeks since the implants, my patients are experiencing a significant improvement in their condition. The implant procedure for the Axonics device is consistent with our current practices, which eliminates any learning curve. Given its long life in the body and ease of recharging, the Axonics r-SNM system represents a major step forward for patients with Fecal Incontinence,” said Dr. Dudding, based at Southampton General Hospital. The Axonics SNM System received CE Mark in early June 2016. To date, over 25 patients have been successfully implanted at leading medical centers in the Netherlands, Belgium, France and the UK as part of a post-market clinical follow-up study (RELAX-OAB) designed to confirm the performance of the Axonics SNM System as an aid in the treatment of the symptoms of Overactive Bladder. The Axonics miniaturized implantable neurostimulator is 60 percent smaller than what is currently available and expected to be functional for at least 15 years in the body, which is more than three times longer than the competitors currently marketed non-rechargeable neurostimulator for SNM. Fecal Incontinence affects an estimated 40 million adults in the U.S. and Europe with an estimated 10 million adults suffering from Dual Incontinence, a combination of Urinary Incontinence and Fecal Incontinence. Sacral Neuromodulation therapy is an effective and durable treatment that has been widely used and reimbursed in Europe and the U.S. for the past two decades. Fecal Incontinence is characterized by the involuntary loss of solid or liquid feces. It is a multifactorial symptom which benefits from limited treatment options as of today. Sacral Neuromodulation has proven to be effective in about 90% of patients who receive the therapy. Axonics, based in Irvine, CA, is a privately held venture backed company developing novel implantable neuromodulation technology directed toward a number of clinical indications. Investors include Edmond de Rothschild Investment Partners, Advent Life Sciences, NeoMed Management, Legend Capital, Cormorant Asset Management and The Alfred E. Mann Foundation. For more information, visit the Company’s website at www.axonicsmodulation.com.


News Article | November 30, 2016
Site: en.prnasia.com

LONDON, Nov. 30, 2016 /PRNewswire/ -- Robert A. Figlin, MD, FACP, joins the 4Dx board on December 1st.  Dr Figlin is Deputy Director of the Integrated Oncology Service Line. He also serves as the Deputy Director at the Samuel Oschin Comprehensive Cancer Institute, part of the world-renowned Cedars-Sinai Medical Center in Los Angeles and is Director of the Hematology Oncology Division at the institute, where he is in charge of integrating research and clinical strategies across all the Cedars-Sinai campuses. Since his arrival at Cedars- Sinai, he established the Experimental Therapeutics Program and successfully recruited clinical research staff in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship, and cancer biology. Dr Figlin says, "4Dx has developed some of the most promising and exciting technology I've ever seen in the fight against disease. It will be a privilege to be able to use my medical and business experience to assist the company through this phase of its growth." Dr Figlin co-founded Agensys - an early stage biotechnology company focussed on developing novel therapies for cancer.  The company has since been sold to Astellas Pharmaceuticals as part of a nine-figure deal. 4Dx founder and chair, Andreas Fouras, says, "Bob Figlin brings unparalleled experience and expertise in cancer therapies to 4Dx, where enhanced cancer treatment is among our first priorities. Bob brings a vast medical knowledge and adds enormous capacity to our board's business decision making capacity." Lung cancer is the biggest killer of all cancers and the current standard treatments of chemotherapy and radiotherapy have devastating effects on the lungs. 4Dx technology is non-invasive and will positively impact the way medical professionals are able to diagnose, and treat their patients. "4Dx is undergoing significant acceleration and is thrilled to have a clinician, researcher and entrepreneurial thinker in Bob Figlan join our team." "This revolutionary technology and the development of unique software to generate moving, ultra-high-resolution images of motion and airflow in lung tissue enables clinicians to view and measure abnormal lung function at the earliest stages of disease in a way that has not been possible before now." As well as their association with Cedars- Sinai, 4Dx has also created partnerships with other leading hospitals such as the Cleveland Clinic and the Children's Hospital Los Angeles in the US, and The Alfred and Peter Mac in Australia. About 4Dx: 4Dx is a software company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders, including, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service scans deliver much more complete results, showing the subtlest variations in lung function down to the finest details, using lower levels of radiation than traditional methods. Respiratory diagnosis is a $25 billion p.a global industry that 4Dx aims to disrupt and grow through technology that provides clinicians with greater insights into diseases of the lung. 4Dx will bring about a step change in lung health by providing better information to doctors and patients.


News Article | February 21, 2017
Site: www.prnewswire.com

NEW YORK, Feb. 21, 2017 /PRNewswire-USNewswire/ -- The Alfred P. Sloan Foundation announces the selection of 126 outstanding U.S. and Canadian researchers as the recipients of the 2017 Sloan Research Fellowships. The fellowships, awarded yearly since 1955, honor those early-career...


News Article | February 21, 2017
Site: www.eurekalert.org

Sebastian Will, an assistant professor in the Department of Physics at Columbia University, has been named a 2017 Sloan Research Fellow. An assistant professor at Columbia since 2016, Will's research interests include ultracold molecules and dipolar quantum gases, quantum simulation and quantum magnetism, and ultracold Fermi gases and Bose-Einstein condensates. It sounds complicated, but Will explained that this area of research is important because it allows for a fundamental understanding about quantum many-body systems. "Simply put," he said, "we're investigating how nature gives order to systems that consist of many interacting particles. In every-day life we see what nature does in basic ways -- stuff can be a solid, a liquid, or a gas - those are the three basic states of matter. However, in the world of quantum mechanics, many more states of matter are possible. One of them is the state of a superconductor - electricity can flow without any resistance, which means no power is lost. With ultracold atoms and molecules we try to understand such quantum states of matter better. This may allow us to design new materials with powerful and technologically relevant properties. Personally, I am most excited that we can observe states of matter in the lab that no one has ever observed before. Who knows what they will be useful for in the future? That's the beauty of fundamental research." The Alfred P. Sloan Foundation awards two-year, $60,000 fellowships to 126 researchers from the United States and Canada annually. The fellowships, awarded since 1955, recognize the distinguished performance of early-career scholars and their unique potential to make substantial contributions to their field. Administered and funded by the foundation, the fellowships are awarded in eight scientific fields: chemistry, computer science, economics, mathematics, evolutionary and computational molecular biology, neuroscience, ocean sciences, and physics. To qualify, candidates must first be nominated by fellow scientists and subsequently selected by an independent panel of senior scholars. "Getting early-career support can be a make-or-break moment for a young scholar," said Paul L. Joskow, president of the Alfred P. Sloan Foundation, in a press release. "In an increasingly competitive academic environment, it can be difficult to stand out, even when your work is first rate. The Sloan Research Fellowships have become an unmistakable marker of quality among researchers. Fellows represent the best-of-the-best among young scientists." "It is a great honor to be selected," Will said. "The Sloan Research Fellowship has an enormous tradition. Among the awardees are some of the greatest physicists, such as Richard Feynman. It is quite amazing to stand on the shoulders of such giants." He added that the money will be used for experiments that deepen the exploration of ultracold molecules. "It will hopefully help to uncover more miracles of the quantum world," he said. Since the beginning of the program, 43 Sloan Fellows have earned Nobel Prizes, 16 have won the Fields Medal in mathematics, 69 have received the National Medal of Science, and 16 have won the John Bates Clark Medal in economics. Other 2017 Sloan Research Fellows include a chemist developing a heat-reflective window paint to help reduce air conditioning demands in hot climates; an evolutionary biologist who models how human gene distributions change with migration; an astronomer using state-of-the-art spectroscopy to study the galaxy's most massive stars; a computer scientist whose work upended a 25-year consensus on algorithmic efficiency; an ocean scientist studying how marine organisms adapt to climate change and the costs of those adaptations; an economist who examines the ways that racial bias among managers can suppress employee productivity; a mathematician developing optimal methods for the efficient analysis of large datasets; and a neuroscientist who studies the way bats learn through echolocation as a model for understanding language development. To learn more about Professor Will's research, visit: http://www.


News Article | February 22, 2017
Site: www.eurekalert.org

Two UC Santa Barbara faculty members -- cryptographer Stefano Tessaro and condensed matter physicist Andrea Young -- have been selected to receive research fellowships from the Alfred P. Sloan Foundation for 2017. The fellowships, awarded yearly since 1955, honor those early-career scholars whose achievements mark them as the next generation of scientific leaders. "Stefano Tessaro, who won an NSF CAREER award last year, is providing a deeper and more rigorous understanding of encryption for cyber security," said Joe Incandela, UCSB interim vice chancellor for research. "Andrea Young has won many awards recently, including one from the Packard Foundation for cutting-edge breakthroughs related to the creation of new states of matter with the potential for extraordinary technological advances -- most notably in ultra-thin graphene samples. We are extremely pleased to have such outstanding young researchers on our campus." Tessaro and Young will each receive a $60,000 fellowship to be used as they wish to further their research. "I am honored and thrilled to have been selected," said Tessaro, whose work focuses on ensuring the security of the encryption algorithms we use every day to send our private information over the internet. "Cryptography has become of paramount importance and its deployment has been growing steadily over the last few years," he added. "The fellowship will support my research efforts in building solid theoretical foundations that support the development of cryptographic methods. The hope is that the answers resulting from this work will play a significant role in securing our digital infrastructure." Andrea Young, meanwhile, develops and investigates the properties of new materials whose behavior reflects the rules of quantum mechanics even on macroscopic scales. "I'm very grateful to Sloan for the recognition," Young said. "Pushing the limits of what we understand about interacting quantum particles is essential for developing electronic devices for the long-term future, and it is far-sighted to invest in a field that can both expand our understanding of basic physics and ultimately yield new functionality for electronic hardware." Past Sloan Research Fellows include many towering scientific figures, including physicists Richard Feynman and Murray Gell-Mann, and game theorist John Nash. Forty-three former fellows have received a Nobel Prize in their respective field, 16 have won the Fields Medal in mathematics, 69 have received the National Medal of Science, and 16 have won the John Bates Clark Medal in economics, including every winner since 2007. "The Sloan Research Fellows are the rising stars of the academic community," said Paul L. Joskow, president of the Alfred P. Sloan Foundation. "Through their achievements and ambition, these young scholars are transforming their fields and opening up entirely new research horizons. We are proud to support them at this crucial stage of their careers." The Alfred P. Sloan Foundation is a philanthropic, not-for-profit grant making institution based in New York City. Established in 1934 by Alfred Pritchard Sloan Jr., then-president and chief executive officer of the General Motors Corporation, the Foundation makes grants in support of original research and education in science, technology, engineering, mathematics, and economics.


News Article | November 30, 2016
Site: www.prnewswire.co.uk

Australian technology start-up 4DX has attracted one of the biggest names in global oncology as its latest Board member. LONDON, Nov. 30, 2016 /PRNewswire/ -- Robert A. Figlin, MD, FACP, joins the 4Dx board on December 1st.  Dr Figlin is Deputy Director of the Integrated Oncology Service Line. He also serves as the Deputy Director at the Samuel Oschin Comprehensive Cancer Institute, part of the world-renowned Cedars-Sinai Medical Center in Los Angeles and is Director of the Hematology Oncology Division at the institute, where he is in charge of integrating research and clinical strategies across all the Cedars-Sinai campuses. Since his arrival at Cedars- Sinai, he established the Experimental Therapeutics Program and successfully recruited clinical research staff in critical specialty areas such as breast cancer, bone marrow transplant, gastrointestinal oncology, genitourinary oncology, survivorship, and cancer biology. Dr Figlin says, "4Dx has developed some of the most promising and exciting technology I've ever seen in the fight against disease. It will be a privilege to be able to use my medical and business experience to assist the company through this phase of its growth." Dr Figlin co-founded Agensys - an early stage biotechnology company focussed on developing novel therapies for cancer.  The company has since been sold to Astellas Pharmaceuticals as part of a nine-figure deal. 4Dx founder and chair, Andreas Fouras, says, "Bob Figlin brings unparalleled experience and expertise in cancer therapies to 4Dx, where enhanced cancer treatment is among our first priorities. Bob brings a vast medical knowledge and adds enormous capacity to our board's business decision making capacity." Lung cancer is the biggest killer of all cancers and the current standard treatments of chemotherapy and radiotherapy have devastating effects on the lungs. 4Dx technology is non-invasive and will positively impact the way medical professionals are able to diagnose, and treat their patients. "4Dx is undergoing significant acceleration and is thrilled to have a clinician, researcher and entrepreneurial thinker in Bob Figlan join our team." "This revolutionary technology and the development of unique software to generate moving, ultra-high-resolution images of motion and airflow in lung tissue enables clinicians to view and measure abnormal lung function at the earliest stages of disease in a way that has not been possible before now." As well as their association with Cedars- Sinai, 4Dx has also created partnerships with other leading hospitals such as the Cleveland Clinic and the Children's Hospital Los Angeles in the US, and The Alfred and Peter Mac in Australia. About 4Dx: 4Dx is a software company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders, including, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer. The unique 4Dx technology accurately and quickly scans lung function as the patient breathes, to provide sensitive, early diagnosis and to monitor changes over time. Our Software-as-a-Service scans deliver much more complete results, showing the subtlest variations in lung function down to the finest details, using lower levels of radiation than traditional methods. Respiratory diagnosis is a $25 billion p.a global industry that 4Dx aims to disrupt and grow through technology that provides clinicians with greater insights into diseases of the lung. 4Dx will bring about a step change in lung health by providing better information to doctors and patients.

Loading The Alfred collaborators
Loading The Alfred collaborators